| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Drug Monitoring, Tapentadol, Quantitative, Urine : 39405
Test CodeQTAPEU or 39405
Alias/See Also
Prescription Drug Monitoring, Pain Management
CPT Codes
80372
Includes
Tapentadol and Nortapentadol
Transport Container
Preferred Specimen
20 mL urine in clinical drug test transport vial
Alternative Specimen
Urine collected in urine collection container
Minimum Volume
5 mL
20 mL urine in clinical drug test transport vial
Alternative Specimen
Urine collected in urine collection container
Minimum Volume
5 mL
Transport Temperature
Refrigerated.
Specimen Stability
Room temperature: 5 days; Refrigerated: 7 days; Frozen: 30 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Preserved samples
Methodology
Mass Spectrometry
Setup Schedule
Varies
Report Available
Varies
Reference Range
Tapentadol <50 ng/mL
Nortapentadol <50 ng/mL
Nortapentadol <50 ng/mL
Clinical Significance
Tapentadol is approved for the treatment of moderate to severe acute pain. Due to its dual mechanism of action as an opioid agonist and norepinephrine reuptake inhibitor, there is potential for ON LABEL for chronic pain. The test is a definitive assay using liquid chromatography mass spectroscopy (LC/MS/MS) methodology. Therapeutic urine drug monitoring of tapentadol is important for ensuring compliance to treatment strategies. Urine or oral fluid are the specimens of choice for routine monitoring of patients taking prescription drugs. Use of serum/plasma should be limited to anuretic patients, or where a patient's clinical appearance does not coincide with their prescribed medications. No single monitoring approach provides adequate information about the pattern or dose of patient drug use. Safest prescribing habits should include a combination of tools and laboratory test results to correctly detect drug use patterns. Quantitative values cannot be used to assess the drug dose, because the drug is extensively metabolized and excreted in the urine.
Performing Laboratory
Quest Diagnostics
